PMID- 10425383
OWN - NLM
STAT- MEDLINE
DCOM- 19990928
LR  - 20191103
IS  - 0928-0987 (Print)
IS  - 0928-0987 (Linking)
VI  - 8
IP  - 4
DP  - 1999 Aug
TI  - Metabolites of mercaptopurine in red blood cells: a relationship between 
      6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in 
      children with lymphoblastic leukemia.
PG  - 329-34
AB  - Intracellular concentrations of 6-mercaptopurine metabolites, i.e. of 
      6-thioguanine nucleotides (6-TGN) and of 6-methylmercaptopurine metabolites 
      (6-mMP) were analysed in red blood cells (RBC) of 19 children with acute 
      lymphoblastic leukemia (ALL), the subjects of a maintenance chemotherapy of their 
      first remission. Interpatient variations in concentrations of both metabolites 
      were high; concentrations of 6-TGN varied from <60 to 833 pmol/8x10(8) RBC 
      (median value, 144) and those of 6-mMP metabolites from <150 to 19000 
      pmol/8x10(8) RBC (median value, 3250). In two patients, 6-TGN appeared at 
      concentrations below the limits of assay sensitivity, and 6-mMP metabolites were 
      not detected. In another child the concentrations of both metabolites were at the 
      limit of the assay sensitivity. In three other children the concentrations of 
      both metabolites were below the median value of the group. In the analysed group 
      of children, significant correlations were found between the white cell count 
      (WBC) and RBC 6-TGN (r(s)=-0.72, P<0. 005) as well as between the neutrophil 
      count and RBC 6-TGN (r(s)=-0.60, P<0.01). No significant correlation was found 
      between the concentrations of 6-TGN and 6-mMP metabolites. The monitoring of 
      concentrations of 6-TGN as well as of 6-mMP metabolites allows an early 
      identification of patients who are at an increased risk of the disease relapse as 
      indicated by the low levels of either 6-TGN itself or of its two metabolites.
FAU - Chrzanowska, M
AU  - Chrzanowska M
AD  - Department of Physical Chemistry, Karol Marcinkowski University of Medical 
      Sciences, Poznan, Poland. mchrzan@eucalyptus.usoms.Poznan.pl
FAU - Kolecki, P
AU  - Kolecki P
FAU - Duczmal-Cichocka, B
AU  - Duczmal-Cichocka B
FAU - Fiet, J
AU  - Fiet J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Guanine Nucleotides)
RN  - 6V404DV25O (6-methylthiopurine)
RN  - E7WED276I5 (Mercaptopurine)
RN  - FTK8U1GZNX (Thioguanine)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adolescent
MH  - Antimetabolites, Antineoplastic/*blood
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Erythrocytes/*metabolism
MH  - Female
MH  - Guanine Nucleotides/*blood
MH  - Humans
MH  - Leukocyte Count
MH  - Male
MH  - Mercaptopurine/administration & dosage/*analogs & derivatives/*blood
MH  - Methotrexate/administration & dosage
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*blood/drug therapy
MH  - Thioguanine/*blood
EDAT- 1999/07/30 00:00
MHDA- 1999/07/30 00:01
CRDT- 1999/07/30 00:00
PHST- 1999/07/30 00:00 [pubmed]
PHST- 1999/07/30 00:01 [medline]
PHST- 1999/07/30 00:00 [entrez]
AID - S0928-0987(99)00027-5 [pii]
AID - 10.1016/s0928-0987(99)00027-5 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 1999 Aug;8(4):329-34. doi: 10.1016/s0928-0987(99)00027-5.